Clinical course of untreated cerebral cavernous malformations: individual patient data meta-analysis by unknown
POSTER PRESENTATION Open Access
Clinical course of untreated cerebral cavernous
malformations: individual patient data meta-analysis
Margaret Horne1*, Kelly Flemming2, I-Chang Su3, Christian Stapf4, Robert Brown Jr2, Teresa Christianson2,
Ronit Agid3, Karel terBrugge3, Robert Willinsky3, Susanne Maxwell1, Gordon Murray1, Rustam Al-Shahi Salman1
From 2nd Clinical Trials Methodology Conference: Methodology Matters
Edinburgh, UK. 18-19 November 2013
Background
The clinical course of untreated cerebral cavernous
malformations (CCM) remains uncertain, partly due to
small sample sizes and the infrequency of outcome
events in previous studies. The dilemma about whether,
when and how to treat patients would be informed by a
more precise estimation of clinical course, identification
of prognostic factors and derivation of prognostic
models.
Method
From a systematic review, we identified three prospective
or retrospective hospital-based cohorts (Mayo Clinic,
Rochester, MN; Toronto Western Hospital, Toronto; and
Hôpital Lariboisière, Paris) and one prospective popula-
tion-based cohort (Scotland) that could provide detailed
data regarding clinical outcome between diagnosis and
CCM treatment or last follow-up in adults with CCM.
We will describe baseline characteristics and use survival
analysis to calculate the risks of outcomes at specific
times and identify their predictors using adjusted hazard
ratios. We will pool the estimates from each study in
meta-analyses using random-effects models, and quantify
and investigate any heterogeneity between studies.
Results
In three cohorts providing data to date (n = 745),
between 29% and 46% of patients presented incidentally,
20-29% with seizure, 13-34% with haemorrhage, and 11-
17% with focal neurological deficit. In follow-up these
cohorts identified 105 symptomatic events, including 46
haemorrhages.
Discussion
A large multinational meta-analysis of CCMs has been
initiated. The inclusion of cohorts and their detailed
data will be finalised by August 2013, with more than
1,000 patients to be included. We will present our initial
results in November 2013. Our findings will help design
future studies of the effects of treatment.
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